These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30522145)

  • 1. Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus.
    Griffin TP; Islam MN; Blake L; Bell M; Griffin MD; O'Shea PM
    Horm Metab Res; 2019 Feb; 51(2):91-99. PubMed ID: 30522145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study.
    Sawamura T; Karashima S; Nagase S; Nambo H; Shimizu E; Higashitani T; Aono D; Ohbatake A; Kometani M; Demura M; Furukawa K; Takeda Y; Yoneda T
    BMC Endocr Disord; 2020 Nov; 20(1):177. PubMed ID: 33256676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of SGLT-2 inhibitors on echocardiographic indices and antioxidative properties in patients with heart failure with reduced ejection fraction and diabetes mellitus.
    Savcılıoglu MD; Duzen IV; Tuluce SY; Savcılıoglu N; Vuruskan E; Altunbas G; Kaplan M; Baloglu M; Tabur S; Sucu M; Taysı S
    Eur Rev Med Pharmacol Sci; 2024 Aug; 28(16):4121-4135. PubMed ID: 39229842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.
    Antlanger M; Domenig O; Kaltenecker CC; Kovarik JJ; Rathkolb V; Müller MM; Schwaiger E; Hecking M; Poglitsch M; Säemann MD; Kopecky C
    Diabetes Obes Metab; 2022 May; 24(5):816-826. PubMed ID: 34984822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
    Røder ME; Storgaard H; Rungby J; Knop FK; Vilsbøll T
    Ugeskr Laeger; 2016 Sep; 178(38):. PubMed ID: 27649712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
    Isshiki M; Sakuma I; Hayashino Y; Sumita T; Hara K; Takahashi K; Shiojima I; Satoh-Asahara N; Kitazato H; Ito D; Saito D; Hatano M; Ikegami Y; Iida S; Shimada A; Noda M
    Endocr J; 2020 Nov; 67(11):1127-1138. PubMed ID: 32612066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
    de Jong MA; Petrykiv SI; Laverman GD; van Herwaarden AE; de Zeeuw D; Bakker SJL; Heerspink HJL; de Borst MH
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):66-73. PubMed ID: 30559106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
    Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
    Moustafa DA; Imran Z; Ismail R; Rayan M; Gadeau AP; Eldassouki H; Abdulrahman N; Mraiche F
    Mol Biol Rep; 2022 Mar; 49(3):2321-2324. PubMed ID: 35102475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
    Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
    ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation].
    Simanenkova AV; Fuks OS; Timkina NV; Sufieva DA; Kirik OV; Korzhevskii DE; Vlasov TD; Karonova TL
    Probl Endokrinol (Mosk); 2024 Sep; 70(4):44-56. PubMed ID: 39302864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
    Assaly R; Gorny D; Compagnie S; Mayoux E; Bernabe J; Alexandre L; Giuliano F; Behr-Roussel D
    J Sex Med; 2018 Sep; 15(9):1224-1234. PubMed ID: 30145094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.
    Lukic N; Macvanin MT; Gluvic Z; Rizzo M; Radak D; Suri JS; Isenovic ER
    Curr Med Chem; 2024; 31(30):4781-4806. PubMed ID: 37855338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
    Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
    Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.